Recently, Lealing Bio and Shanghai Pharmaceutical Group Biotherapy Technology Co., Ltd. (hereinafter referred to as “SP Biotherapy”) conducted special exchanges focusing on the transformation of cell therapy technology and the development of the big health industry. Both parties in-depth discussed core topics, highly recognized each other’s technological strength and resource advantages, and reached multiple consensuses on future cooperation directions and technological application potential.
Jointly Promote Clinical Research of Universal NKT Cell Therapy Targeting Intracellular Antigens
During the exchange, both parties identified the clinical advancement of universal NKT cell therapy targeting intracellular antigens as a core topic. This globally pioneering cell therapy can not only break through the limitations of cell membrane antigens but also effectively address the industry pain points of high cost and long preparation cycle in current personalized cell therapy, making it a key direction for the large-scale application of cell therapy.
Hua Jian, General Manager of SP Biotherapy, stated that Lealing Bio has obvious advantages in innovative capabilities in target discovery, molecule identification and optimization, and preclinical validation, which are highly aligned with SP Biotherapy’s goal of promoting the industrialization of cell therapy. Meanwhile, SP Biotherapy’s mature experience in clinical application, compliance system construction, and industrialization implementation can provide key support for technological transformation. The complementary advantages of both parties will accelerate the process from early discovery to clinical transformation of the technology, bringing more treatment options to patients.
Dr. Wang Wenbo pointed out that in the field of cancer treatment, the patient’s immune status needs to be considered. Tumor progression and long-term medication can damage the immune system, which may lead to poor efficacy of TCE drugs and the currently popular in vivo CAR-T therapy. Exogenously supplemented universal NKT cells can not only directly kill and control tumors but also have the potential to partially restore the patient’s immune system, achieving a dual effect.
Explore the Application of Lealing’s Self-Developed Leaimmunecenter® Technology Platform in B-Cell Depletion Therapy and Big Health Sectors
Regarding Leaimmunecenter®, Lealing Bio’s independently developed immunoprofiling solution platform, both parties focused on discussing its clinical diagnostic value in B-cell depletion therapy. By detecting clones of different BCR subtypes, this platform accurately monitors the reconstruction process of B cells, providing a clinical auxiliary diagnostic tool for B-cell depletion therapy in all autoimmune diseases.
General Manager Hua highly recognized the Leaimmunecenter® technology platform, noting that it will provide a differentiated technical solution for B-cell depletion therapy. It is expected to address the limitations and cost issues of flow cytometry and single-cell sequencing technologies, possessing broad clinical application value.
In addition, General Manager Hua stated that as a new type of precise immune assessment tool, the Leaimmunecenter® platform can cooperate and integrate with the technical platform already built by SP Biotherapy, and be applied to important tracks in the big health industry such as immune aging intervention. The precise immune capability of the Leaimmunecenter® platform can provide core technical support for this field. In the future, it is expected to develop more products meeting public health needs. Meanwhile, the channel layout and brand influence of the big health industry will help transform the technology into market-oriented products, allowing the platform’s value to serve public health faster and promoting the development of the big health industry.
This exchange has built a good communication bridge for the subsequent cooperation between both parties. In the future, both parties will continue to promote the connection in technological research and development, clinical transformation and other fields, promote development through cooperation, jointly drive the innovation of cell therapy technology and the upgrading of the big health industry, and contribute to the development of the medical and health field.
